<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405715</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR-12678</org_study_id>
    <nct_id>NCT02405715</nct_id>
  </id_info>
  <brief_title>Therapy With an Oxytocin Adjunct for Major Depression</brief_title>
  <acronym>TOAD2015</acronym>
  <official_title>Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concordia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concordia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression
      using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to
      interpersonal psychotherapy, and the other half will receive oxytocin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is a debilitating mental health condition that carries great consequences for both
      the individual and society. Crucially, at least one third of depressed patients do not
      respond to existing interventions and relapse rates are high, alerting scientists to the need
      to explore possible adjunctive treatments and novel therapeutic targets. In this regard,
      research on the use of oxytocin in the treatment of depression is promising.

      It is well documented that interpersonal stress predicts the onset of depression, and that
      social isolation is a symptom of psychological distress that can leave patients with a poor
      prognosis for recovery. Therapeutic interventions focused on the alleviation of social
      conflict and strengthening of social bonds (i.e. Interpersonal Psychotherapy; IPT) show
      greater efficacy for the treatment of depression than other psychological interventions (NIMH
      Treatment of Depression Collaborative Research Program; Elkin et al. 1984). It has been
      posited that oxytocin, a naturally produced hormone that is involved in social-support
      seeking and stress-regulation, could represent a biological link between social stress and
      depression in adulthood. The salubrious effect of exogenous oxytocin on human social behavior
      is well documented: Oxytocin has been shown to make individuals feel more securely attached
      in their social relationships, increase their trust in others and openness to new ideas,
      improve their recall of specific and positive social autobiographical memories, and improve
      social learning. Importantly, these factors have been shown to improve the efficacy of
      Interpersonal Psychotherapy. Thus, It stands to reason that the use of oxytocin as an adjunct
      to IPT could improve its efficacy for the treatment of depression, which is an important
      prospect when considering that a third of patients do not respond to existing therapies.

      In the proposed research project, we will conduct a Randomized Controlled Trial for the
      treatment of Major Depression with IPT and adjunctive oxytocin. Patients will be screened for
      eligibility, undergo structured psychotherapy for twelve weeks, and will be followed
      longitudinally for changes in quality of social functioning, interpersonal stress,
      psychiatric symptoms and depressive relapse. Establishing novel interventions for depression
      could position healthcare providers to better alleviate the burden and personal suffering
      caused by this disorder.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>Hamilton Rating Scale for Depression (HRS-D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>Inventory for Depressive Symptomology (IDS-C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>Global Axis of Functioning using the SCID-IV (GAF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient dropout rate [Number of sessions missed]</measure>
    <time_frame>includes baseline up to 4 months following baseline assessment (until the end of therapy)</time_frame>
    <description>patient dropout rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive Symptoms (patient-rated) (Beck Depression Inventory-II (BDI-II) [Change Score]</measure>
    <time_frame>Baseline up to 10 months later (slope of change over time)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D) [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>Hamilton Rating Scale for Depression (HRS-D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>Inventory for Depressive Symptomology (IDS-C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>Global Axis of Functioning using the SCID-IV (GAF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>UCLA Life Stress Interview - Chronic Stress Module (UCLA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological stress reactivity (Daily Diurnal Cortisol) [Change Score]</measure>
    <time_frame>Baseline, 4 months later (following therapy)</time_frame>
    <description>Daily Diurnal Cortisol (2 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working alliance (clinician-rated) (Working Alliance Inventory (WAI) [Change Score]</measure>
    <time_frame>Baseline up to 4 months later (slope of change over time)</time_frame>
    <description>Working Alliance Inventory (WAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social functioning (patient-rated) (Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS) COMPOSITE SCORE [Change Score]</measure>
    <time_frame>Baseline up to 10 months later (slope of change over time)</time_frame>
    <description>Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress (patient-rated) (Perceived Stress Scale (PSS) [Change Score]</measure>
    <time_frame>Baseline up to 10 months later (slope of change over time)</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety (patient-rated) (Beck Anxiety Inventory (BAI) [Change Score]</measure>
    <time_frame>Baseline up to 10 months later (slope of change over time)</time_frame>
    <description>Beck Anxiety Inventory (BAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Alliance (patient-rated) (Working Alliance Inventory (WAI)</measure>
    <time_frame>Baseline up to 4 months later (slope of change over time)</time_frame>
    <description>Working Alliance Inventory (WAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usefulness of Therapy (patient-rated); COMPOSITE SCORE</measure>
    <time_frame>Baseline up to 4 months later (slope of change over time)</time_frame>
    <description>Measure by score on Helpful Aspects of Therapy (HAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>UCLA Life Stress Interview - Chronic Stress Module (UCLA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological stress reactivity (Daily Diurnal Cortisol) [Change Score]</measure>
    <time_frame>4 months later (following therapy) and 10 months later (6 months following therapy)</time_frame>
    <description>Daily Diurnal Cortisol (2 days)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Moderation by personality (NEO-PI-R)</measure>
    <time_frame>Baseline</time_frame>
    <description>NEO-PI-R; Moderation by extraversion</description>
  </other_outcome>
  <other_outcome>
    <measure>Mediation by personality (NEO-PI-R) [Change Score]</measure>
    <time_frame>Baseline up to 10 months later [Slope of Change]</time_frame>
    <description>NEO-PI-R; Mediation by extraversion</description>
  </other_outcome>
  <other_outcome>
    <measure>Moderation by attachment (ECR, AAI) [COMPOSITE SCORE]</measure>
    <time_frame>Baseline</time_frame>
    <description>ECR, AAI: Moderation by attachment style</description>
  </other_outcome>
  <other_outcome>
    <measure>Moderation by attachment (ECR, AAI) [COMPOSITE SCORE]</measure>
    <time_frame>Baseline up to 10 months later [Slope of Change]</time_frame>
    <description>ECR, AAI: Mediation by attachment style</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events [Average Score] COMPOSITE</measure>
    <time_frame>baseline up to 4 months</time_frame>
    <description>In-house measure of adverse events weekly</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo Spray And Interpersonal Psychotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin Spray And Interpersonal Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Oxytocin Spray And Interpersonal Psychotherapy</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        â€¢ Current Major Depressive Episode

        Exclusion Criteria

          -  Visual impairment

          -  Major medical illness [A condition that is chronic and associated with impaired
             functioning, distress, or frequent medical intervention), in particular, subjects with
             evidence or history of malignancy or any significant hematological, endocrine,
             cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or
             gastrointestinal disease

          -  Acute or chronic nasal diseases or obstruction

          -  Current (in the last month) use of any endocrine-relevant or psychotropic medication
             other than prescription antidepressants

          -  Current substance dependence or abuse

          -  Use of illicit drugs (stimulants, narcotics, psychedelics/hallucinogens,
             non-prescription medication) in the past 8 weeks

          -  Lifetime history of a psychosis (except if part of MDD) or pervasive developmental
             disorder

          -  Past or current comorbid axis-1 disorder except Dysthymia, Adjustment Disorder,
             Generalized Anxiety Disorder, Social Phobia, and Specific Phobia.

          -  Female Only: Females of child bearing potential cannot be pregnant or breastfeeding in
             order to participate in this study. They must not be planning to become pregnant, and
             must be willing to use appropriate contraception throughout the study.

          -  Female Only: To control for hormonal changes related to pregnancy, females will also
             be excluded if they have previously given birth.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Ellenbogen, PhD</last_name>
    <phone>514 848 2424</phone>
    <phone_ext>7543</phone_ext>
    <email>mark.ellenbogen@concordia.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Cardoso, MA</last_name>
    <phone>514 848 2424</phone>
    <phone_ext>5456</phone_ext>
    <email>christophercardoso@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Concordia University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4B 1R6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ellenbogen, PhD</last_name>
      <phone>514 848 2424</phone>
      <phone_ext>7543</phone_ext>
      <email>mark.ellenbogen@concordia.ca</email>
    </contact>
    <contact_backup>
      <last_name>Christopher Cardoso, MA</last_name>
      <phone>514 848 2424</phone>
      <phone_ext>5456</phone_ext>
      <email>christophercardoso@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Concordia University</investigator_affiliation>
    <investigator_full_name>Mark Ellenbogen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

